| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
CD25 (IL-2Ralpha, alpha chain of the interleukin-2 receptor). Inolimomab binds to CD25 expressed on activated T cells and regulatory T cells, blocking the binding of IL-2 to the high-affinity IL-2 receptor. This prevents IL-2-mediated T-cell activation and proliferation.
|
|---|---|
| ln Vitro |
In vitro, Inolimomab binds to CD25 on the surface of activated human T cells. It inhibits IL-2-induced T-cell proliferation in a dose-dependent manner, as measured by [3H]-thymidine incorporation. It also blocks IL-2-dependent signaling, including STAT5 phosphorylation, in CD25+ T-cell lines such as Kit225.
|
| ln Vivo |
In animal models of acute graft-versus-host disease (aGVHD), such as the parent-into-F1 or human PBMC-engrafted NSG mouse model, Inolimomab improves survival rates and reduces clinical signs of GVHD (e.g., weight loss, skin lesions, diarrhea). It decreases the expansion of donor T cells and lowers serum levels of pro-inflammatory cytokines like IFN-gamma and TNF-alpha.
|
| Enzyme Assay |
A direct binding ELISA is used: recombinant human CD25 (IL-2Ralpha) protein is coated onto microtiter plates. Serially diluted Inolimomab is added, and bound antibody is detected using an HRP-conjugated anti-mouse IgG secondary antibody. The EC50 for binding is calculated from the dose-response curve.
|
| Cell Assay |
The inhibition of T-cell proliferation is measured using human PBMCs stimulated with phytohemagglutinin (PHA) or anti-CD3/anti-CD28 antibodies. PBMCs are cultured in the presence of serially diluted Inolimomab (e.g., 0.1-100 ug/mL) for 72-96 hours. Cell proliferation is assessed by adding [3H]-thymidine for the final 16-18 hours and measuring incorporation with a beta counter. Alternatively, CFSE dilution is analyzed by flow cytometry.
|
| Animal Protocol |
The efficacy of Inolimomab is evaluated in a humanized mouse model of aGVHD. Immunodeficient NSG mice are injected intravenously with human PBMCs (10-20 × 10⁶ cells/mouse) to induce xenogeneic GVHD. Inolimomab is administered intraperitoneally at doses of 5-20 mg/kg every 3 days, starting on day 0 or day 7 post-PBMC injection. Survival curves are generated over 4-8 weeks, and mice are scored weekly for clinical signs of GVHD (weight loss, hunched posture, skin integrity).
|
| ADME/Pharmacokinetics |
As a mouse monoclonal antibody, Inolimomab has a shorter half-life (~5-8 days in humans) compared to humanized or fully human antibodies. The volume of distribution is consistent with the vascular space, and clearance is moderate. Pharmacokinetic studies in rodents show a dose-proportional increase in Cmax and AUC following intraperitoneal or intravenous administration.
|
| Toxicity/Toxicokinetics |
Inolimomab is generally well-tolerated, but as a mouse antibody, it may elicit immunogenicity and infusion-related reactions in humans. The most commonly reported adverse events in clinical studies were mild-to-moderate infusion reactions (e.g., fever, chills, rash), and no dose-limiting toxicities were observed at therapeutic doses in aGVHD trials.
|
| References |
|
| Additional Infomation |
Inolimomab has been evaluated in clinical trials for the treatment of acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). It has not received regulatory approval for any indication and is not currently marketed. It is available for research purposes to study CD25-mediated immunosuppression and to explore T-cell activation pathways.
|
| CAS # |
152981-31-2
|
|---|---|
| Appearance |
Colorless to light yellow liquid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
